Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Distribution01:00

Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Distribution

299
Drug distribution in the human body is influenced by several factors, including plasma protein concentration, body composition, blood flow, tissue-protein concentration, and tissue fluid pH. Among these, changes in plasma protein concentration and body composition due to aging significantly affect how drugs are distributed within the body. Specifically, aging is associated with a decrease in albumin levels by about 10% and an increase in α1-acid glycoprotein levels. These alterations are...
299
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Absorption01:22

Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Absorption

764
As individuals age, their body's physiology evolves, affecting drug pharmacokinetics. The most apparent changes occur in the gastrointestinal tract, where an increase in gastric pH, a delay in gastric emptying, and a reduction in gastrointestinal motility are observed. Remarkably, these changes do not substantially modify the absorption of orally administered drugs, particularly those absorbed via passive diffusion.Transdermal drug delivery emerges as a highly viable method for older adults due...
764
Pharmacodynamics in Geriatric Patients: Effects of Age01:27

Pharmacodynamics in Geriatric Patients: Effects of Age

282
Age-related pharmacokinetic changes are extensively documented, but understanding age-related pharmacodynamic alterations is relatively limited. This knowledge gap can be partly attributed to the complexity of developing appropriate measures of drug responses compared to bioanalytical methods for determining drug concentrations.Most information regarding age-related differences in human pharmacodynamics originates from cross-sectional studies. However, these studies assume that observed mean...
282
Drug Dosing: Geriatric Patients01:15

Drug Dosing: Geriatric Patients

325
Elderly individuals encompass a diverse population with varying degrees of age-related physiological changes. Defining the elderly presents challenges, as the geriatric population is often arbitrarily categorized as individuals older than 65. However, many individuals in this group lead active and healthy lives, with an increasing number surpassing 85 years and falling into the older elderly category. Physiological changes associated with aging impact performance capacity and homeostatic...
325
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism01:18

Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism

272
Geriatric patients show significant variation in how their bodies process medications, which can change how effective and safe treatments are. The liver is the primary organ where drug metabolism occurs, involving two main types of chemical reactions: phase I and II. Phase I metabolism is driven by the cytochrome P450 enzyme system, which includes key types such as CYP3A, CYP2D6, and CYP2C9. Research indicates that while aging doesn't notably alter the levels or activity of these enzymes, it...
272
Pharmacokinetics in Obese Patients: Drug Absorption and Distribution01:25

Pharmacokinetics in Obese Patients: Drug Absorption and Distribution

322
Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
322

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Response to Boland et al. "Appraisal of the references supporting STOPP/START version 3 criteria".

European geriatric medicine·2026
Same author

[Advocating for geriatrics: a necessary endeavour that requires perseverance].

Revista espanola de geriatria y gerontologia·2026
Same author

Sarcopenia in Diabetes: A proposal on integrating muscle assessment and nutritional intervention in people living with diabetes.

Diabetes research and clinical practice·2026
Same author

Current application and future directions for the sarcopenic obesity Global Leadership Initiative (SOGLI) diagnostic algorithm.

Clinical nutrition (Edinburgh, Scotland)·2026
Same author

Validity, reliability, and diagnostic accuracy of the InGrip digital dynamometer compared with the Jamar hydraulic model in older adults.

European geriatric medicine·2026
Same author

Nutritional care using oral nutritional supplements: 22 questions every clinician Asks-Answered by global experts in a Delphi consensus study.

Clinical nutrition (Edinburgh, Scotland)·2026

Related Experiment Video

Updated: Feb 27, 2026

The Creation of a Rat Model for Osteosarcopenia via Ovariectomy
03:52

The Creation of a Rat Model for Osteosarcopenia via Ovariectomy

Published on: February 21, 2025

1.4K

Sarcopenia: what should a pharmacist know?

Alfonso J Cruz-Jentoft1

  • 1Geriatrics Unit. Hospital Universitario Ramón y Cajal (IRYCIS), Madrid.. ajcruzjentoft@me.com.

Farmacia Hospitalaria : Organo Oficial De Expresion Cientifica De La Sociedad Espanola De Farmacia Hospitalaria
|July 8, 2017
PubMed
Summary
This summary is machine-generated.

Sarcopenia, a geriatric syndrome of muscle loss, leads to disability and falls. Early prevention through nutrition and exercise, plus resistance training and protein intake, are key treatments.

More Related Videos

Semi-Targeted Ultra-High-Performance Chromatography Coupled to Mass Spectrometry Analysis of Phenolic Metabolites in Plasma of Elderly Adults
14:39

Semi-Targeted Ultra-High-Performance Chromatography Coupled to Mass Spectrometry Analysis of Phenolic Metabolites in Plasma of Elderly Adults

Published on: April 22, 2022

4.5K
Author Spotlight: Assessing Surgical Frailty with Point-of-Care Ultrasound of Quadriceps Muscles
04:00

Author Spotlight: Assessing Surgical Frailty with Point-of-Care Ultrasound of Quadriceps Muscles

Published on: July 26, 2024

1.4K

Related Experiment Videos

Last Updated: Feb 27, 2026

The Creation of a Rat Model for Osteosarcopenia via Ovariectomy
03:52

The Creation of a Rat Model for Osteosarcopenia via Ovariectomy

Published on: February 21, 2025

1.4K
Semi-Targeted Ultra-High-Performance Chromatography Coupled to Mass Spectrometry Analysis of Phenolic Metabolites in Plasma of Elderly Adults
14:39

Semi-Targeted Ultra-High-Performance Chromatography Coupled to Mass Spectrometry Analysis of Phenolic Metabolites in Plasma of Elderly Adults

Published on: April 22, 2022

4.5K
Author Spotlight: Assessing Surgical Frailty with Point-of-Care Ultrasound of Quadriceps Muscles
04:00

Author Spotlight: Assessing Surgical Frailty with Point-of-Care Ultrasound of Quadriceps Muscles

Published on: July 26, 2024

1.4K

Area of Science:

  • Geriatrics
  • Muscle Physiology
  • Aging Research

Background:

  • Sarcopenia is a progressive geriatric syndrome involving loss of skeletal muscle mass and function.
  • It leads to adverse outcomes including physical disability, falls, and mortality.
  • Sarcopenia can develop chronically over years or acutely due to immobilization.

Purpose of the Study:

  • To define sarcopenia, its complex pathophysiology, and prevalence.
  • To outline diagnostic criteria based on muscle mass, strength, and performance.
  • To detail prevention and treatment strategies for sarcopenia.

Main Methods:

  • Diagnosis involves assessing low muscle mass combined with low muscle strength and/or physical performance.
  • A comprehensive geriatric assessment is crucial for identifying causes and tailoring treatment.
  • Prevention strategies include adequate nutrition and physical activity from adulthood.
  • Treatment focuses on resistance exercises, improved diet (1.2-1.5g/kg/day protein), and caloric adequacy.

Main Results:

  • Prevalence increases with age and in healthcare settings like nursing homes.
  • Nutritional supplements (leucine, HMB, vitamin D) may optimize treatment effects.
  • No specific medications are currently available for sarcopenia treatment.

Conclusions:

  • Sarcopenia requires a syndromic approach combining symptom management and etiological treatment.
  • Resistance exercise and nutritional interventions are fundamental to managing sarcopenia.
  • Early prevention and timely intervention are critical for mitigating sarcopenia's impact.